This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
2010 Childhood, Adolescent, Adult Immunization Schedules Released
HPV Vaccination Options Among Changes for Adults, Adolescents
By News Staff
In October, the ACIP recommended routine use of Cervarix, a bivalent HPV vaccine manufactured by GlaxoSmithKline Biologicals, or GSK, after it was approved by the FDA for the prevention of cervical cancer and precancerous lesions caused by HPV types 16 and 18 in girls and women ages 10-25.
Like Gardasil, Merck & Co. Inc.'s quadrivalent HPV vaccine, Cervarix is administered in a three-dose series. Cervarix does not protect against the HPV types that cause genital warts, but either vaccine can be used to prevent cervical cancer and precancerous lesions in young women.
The HPV footnote in the adult schedule also includes new information indicating that ACIP supports permissive use of the quadrivalent vaccine in males as old as 26 for the prevention of genital warts.
Similar updates about the new bivalent HPV vaccine in girls and young women and the use of the quadrivalent vaccine in boys and young men also appear in the 2010 adolescent immunization schedule, which -- along with the children's immunization schedule and the child and adolescent catch-up schedule -- was produced by the ACIP in conjunction with AAFP and the American Academy of Pediatrics.
The 2010 adult schedule includes several other changes:
- In the revised footnote for measles, mumps and rubella, or MMR, vaccine, the groups call for health care facilities to recommend that unvaccinated health care workers who were born before 1957 and who lack laboratory evidence of immunity or confirmation of disease receive two doses of MMR vaccine during an outbreak of measles or mumps and one dose during an outbreak of rubella. Interval dosing information also has been added to indicate that when a second dose of MMR is indicated, it should be administered four weeks after the first dose.
- The meningococcal vaccine footnote has been updated to clarify that the meningococcal conjugate vaccine, or MCV4, is preferred for adults ages 55 and younger and that the meningococcal polysaccharide vaccine, or MPSV4, is preferred for adults 56 and older. Revaccination with MCV4 after five years is recommended for adults previously vaccinated with MCV4 or MPSV4 who remain at high risk for meningococcal infection, such as those with asplenia.
- The hepatitis A footnote has been updated to include an indication for unvaccinated people who anticipate close contact with an international adoptee from a country where hepatitis A is endemic.
- The hepatitis B footnote has been updated to include scheduling information for the three-dose vaccine series.
Other changes to the children's schedule include revisions of recommendations for the inactivated poliovirus vaccine. The last dose in the series now is recommended to be administered on or after a child's fourth birthday and at least six months after the previous dose. If four doses are administered before age 4 years, a fifth dose should be administered at age 4 through 6 years.
Finally, revaccination with MCV4 is recommended for children who remain at increased risk for the disease. Children should be revaccinated after three years if the first dose was administered at age 2 through 6 years, or after five years if the first dose was administered at age 7 or older.
ACIP Supports 'Permissive Use,' But Not Routine Use, of Gardasil in Males
Committee Recommends Use of GSK's New Bivalent HPV Vaccine in Females
New ACIP Provisional Recs Cover Multiple Immunization Topics
Panel Expresses 'General Preference' for Combination vs. Component Vaccines
Vaccines & Immunizations Special Report
More From AAFP